

GenMark Diagnostics, Inc.  
Form 8-K  
May 02, 2012

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 27, 2012

**GENMARK DIAGNOSTICS, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-34753**  
(Commission  
File Number)

**27-2053069**  
(I.R.S. Employer  
Identification No.)

Edgar Filing: GenMark Diagnostics, Inc. - Form 8-K

**5964 La Place Court, Suite 100**

**Carlsbad, California**  
(Address of principal executive offices)

**760-448-4300**

**92008**  
(Zip Code)

(Registrant's telephone number, including area code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

(e) On April 2, 2012, Genmark Diagnostics, Inc. (the Company ) reported that Richard B. Slansky was named as Chief Financial Officer of the Company effective April 23, 2012, succeeding Paul Ross, the Company's former Chief Financial Officer. In connection with Mr. Ross' separation from the Company and in exchange for Mr. Ross' agreement to enter into a separation agreement and general release of claims in favor of the Company, the Company has agreed to (i) pay to Mr. Ross a salary continuation benefit of \$100,000, less applicable taxes, payable in ten semi-monthly increments and (ii) reimburse Mr. Ross for the premiums for health coverage through COBRA for a maximum of five months, unless Mr. Ross earlier becomes eligible for health coverage through a subsequent employer.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 2, 2012

**GENMARK DIAGNOSTICS, INC.**

/s/ Matthew R. Cohen

Matthew R. Cohen

Senior Vice President, General Counsel and Corporate Secretary